生產(chǎn)地：品牌：MedChemExpress （MCE）

移動(dòng)電話：18019480960公司傳真：86-021-53700325

更新時(shí)間：2019-07-02

MedChemExpress (MCE) 專注于為全球科學(xué)家提供高品質(zhì)的生物活性小分子化合物，化合物庫及各類試劑盒，總部位于美國新澤西。
 MedChemExpress (MCE) 產(chǎn)品作用于 20 多個(gè)熱門信號通路及研究領(lǐng)域的300多個(gè)細(xì)分靶點(diǎn)，擁有 10000 特異性抑制劑、激動(dòng)劑，以及 30 活性化合物篩選庫；
 我們堅(jiān)持對所有產(chǎn)品進(jìn)行嚴(yán)格質(zhì)檢，確保產(chǎn)品的高品質(zhì)和高純度；
 MedChemExpress (MCE) 產(chǎn)品已被全球數(shù)萬名科學(xué)家信賴，并被大量Top文獻(xiàn)和Patent引用；
 我們擁有專業(yè)的技術(shù)團(tuán)隊(duì)追蹤全球前沿科技進(jìn)展，不斷豐富各個(gè)靶點(diǎn)的特異性產(chǎn)品，堅(jiān)持做 您身邊的抑制劑大師 ；
 MedChemExpress (MCE) 與全球眾多知名藥企和科研機(jī)構(gòu)保持深度合作；
 大量產(chǎn)品有中國庫存，工作日 16:00 前訂單確保當(dāng)日發(fā)貨，次日送達(dá)。
MCE 中國：www.MedChemExpress.cn

Hotline: 400-820-3792
Tel: 021-58955995
Email: sales@MedChemExpress.cn
Tech Support: 021-58950656

產(chǎn)品活性：MBQ-167 是 Ras 相關(guān)的 C3 型肉毒素底物 (Rac) 和細(xì)胞分裂周期蛋白 (Cdc42) 的雙抑制劑，其對 Rac 1/2/3 的 IC50 值為 103 nM， 對 Cdc42 的 IC50 值為 78 nM。

研究領(lǐng)域：GPCR/G Protein | Cell Cycle/DNA Damage

作用靶點(diǎn)：Ras | CDK

In Vitro: MBQ-167 (≥100 nM) induces a loss of polarity in metastatic breast cancer cells. Treatment with 500 nM MBQ-167 for 24 h results in ~95% cell rounding and detachment from the substratum in metastatic MDA-MB-231 cells. Moreover, MBQ-167 induces this phenotype in multiple mesenchymal cancer cell types including GFP-HER2-BM, MDA-MB-468, and Hs578t human breast cancer cells, as well as Mia-PaCa-2 pancreatic cancer cells, SKOV3 ovarian cancer cells, AGS and NCI-N87 gastric cancer cells, and SH-SY5Y neuroblastoma cells. Following treatment with 250 nM MBQ-167 for 24 h, the attached population of MDA-MB-231 cells demonstrate a ~25% decrease in Rac activation while the detached cells are more responsive with a ~75% decrease. At earlier times (6h), treatment with 250 or 500 nM MBQ-167, induce a inhibition in Rac activity in the attached cell population, while the detached population demonstrate a ~40-50% inhibition.

In Vivo: MBQ-167-treated mice demonstrate a statistically significant reduction in tumor growth. At sacrifice, 1.0 mg/kg BW of MBQ-167 results in a ~80% reduction in tumor growth, and the 10 mg/kg BW MBQ-167 treatment results in ~95% reduction in tumor growth. Since EHop-016 only exerts ~40% reduction of tumor growth at 10 mg/kg BW, MBQ-167 is 10X more effective than EHop-016. MBQ-167 treated mice demonstrate similar doubling times for both treatments (10 and 11 days).

相關(guān)產(chǎn)品：Kinase Inhibitor Library | GPCR/G Protein Compound Library | Anti-Cancer Compound Library | Cell Cycle/DNA Damage Compound Library | Bioactive Compound Library Plus | Palbociclib | Abemaciclib methanesulfonate | Ribociclib | Dinaciclib | THZ531 | ARS-1620 | THZ1 | Seliciclib | NVP-2 | Ro-3306 | Flavopiridol | ARS-853 | CYC065 | Atuveciclib Racemate | NSC 23766 trihydrochloride | AZD4573 | ML141 | GSK 3 Inhibitor IX | Pan-RAS-IN-1 | SNS-032 | SB1317 | Kenpaullone | Rhosin hydrochloride | CDK9-IN-2 | Salirasib | AZD-5438